|
US3705185A
(en)
|
1969-04-14 |
1972-12-05 |
Minnesota Mining & Mfg |
N-aroyl sulfonamides
|
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
EP0102324A3
(de)
|
1982-07-29 |
1984-11-07 |
Ciba-Geigy Ag |
Lipide und Tenside in wässriger Phase
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
DK24089D0
(da)
|
1989-01-20 |
1989-01-20 |
Hans Bundgaard |
Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
|
|
GB8911854D0
(en)
|
1989-05-23 |
1989-07-12 |
Ici Plc |
Heterocyclic compounds
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
US5112596A
(en)
|
1990-04-23 |
1992-05-12 |
Alkermes, Inc. |
Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
|
|
AU1625192A
(en)
|
1991-05-31 |
1992-12-03 |
Zeneca Limited |
Heterocyclic derivatives
|
|
EP0567997A1
(de)
*
|
1992-04-30 |
1993-11-03 |
Hoechst Aktiengesellschaft |
4- oder 5-(Sulf)imido- und (Sulfon)amidopyridine, sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
AU677216B2
(en)
|
1992-07-27 |
1997-04-17 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Targeting of liposomes to the blood-brain barrier
|
|
JP3462501B2
(ja)
|
1992-11-23 |
2003-11-05 |
アベンティス・ファーマスーティカルズ・インコーポレイテツド |
置換された３−（アミノアルキルアミノ）−１，２−ベンゾイソキサゾールおよび関連化合物
|
|
US5573653A
(en)
|
1994-07-11 |
1996-11-12 |
Sandoz Ltd. |
Electrochemical process for thiocyanating aminobenzene compounds
|
|
GB9514160D0
(en)
*
|
1994-07-25 |
1995-09-13 |
Zeneca Ltd |
Aromatic compounds
|
|
NZ291508A
(en)
|
1994-08-30 |
1999-07-29 |
Sankyo Co |
Isoxazoles; preparation and medicaments
|
|
US5753653A
(en)
|
1995-12-08 |
1998-05-19 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
|
GB9828442D0
(en)
*
|
1998-12-24 |
1999-02-17 |
Karobio Ab |
Novel thyroid receptor ligands and method II
|
|
JP4316787B2
(ja)
*
|
2000-01-11 |
2009-08-19 |
壽製薬株式会社 |
エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
|
|
US6514221B2
(en)
|
2000-07-27 |
2003-02-04 |
Brigham And Women's Hospital, Inc. |
Blood-brain barrier opening
|
|
WO2002015902A1
(en)
*
|
2000-08-23 |
2002-02-28 |
Merck & Co., Inc. |
Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
|
|
AU2001286930A1
(en)
|
2000-08-30 |
2002-03-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
|
US7034036B2
(en)
|
2000-10-30 |
2006-04-25 |
Pain Therapeutics, Inc. |
Inhibitors of ABC drug transporters at the blood-brain barrier
|
|
DE10121982B4
(de)
|
2001-05-05 |
2008-01-24 |
Lts Lohmann Therapie-Systeme Ag |
Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
|
|
CA2450073C
(en)
|
2001-07-25 |
2017-08-29 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
|
KR100789567B1
(ko)
|
2001-11-06 |
2007-12-28 |
동화약품공업주식회사 |
3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
|
|
DE10201550A1
(de)
|
2002-01-17 |
2003-07-31 |
Merck Patent Gmbh |
Phenoxy-Piperidine
|
|
US20030162695A1
(en)
|
2002-02-27 |
2003-08-28 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
|
US7332486B2
(en)
|
2002-08-08 |
2008-02-19 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
|
JP4995423B2
(ja)
|
2002-12-03 |
2012-08-08 |
ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート |
物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
|
|
GT200300283A
(es)
*
|
2002-12-12 |
2004-07-14 |
|
Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
|
|
MY141521A
(en)
*
|
2002-12-12 |
2010-05-14 |
Hoffmann La Roche |
5-substituted-six-membered heteroaromatic glucokinase activators
|
|
CA2521915A1
(en)
|
2003-04-15 |
2004-10-28 |
Pfizer Inc. |
Alpha substituted carboxylic acid as ppar modulators
|
|
CN1863785A
(zh)
|
2003-08-08 |
2006-11-15 |
沃泰克斯药物股份有限公司 |
在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
|
|
KR20060073930A
(ko)
|
2003-08-08 |
2006-06-29 |
버텍스 파마슈티칼스 인코포레이티드 |
통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
|
|
WO2005025511A2
(en)
|
2003-09-10 |
2005-03-24 |
Cedars-Sinai Medical Center |
Potassium channel mediated delivery of agents through the blood-brain barrier
|
|
PL1668002T3
(pl)
|
2003-10-03 |
2010-02-26 |
Portola Pharm Inc |
2,4-diokso-3-chinazolinyloarylowe pochodne sulfonylomocznika
|
|
US7081539B2
(en)
|
2004-03-25 |
2006-07-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide
|
|
MY134672A
(en)
|
2004-05-20 |
2007-12-31 |
Japan Tobacco Inc |
Stable crystal of 4-oxoquinoline compound
|
|
CA2574971A1
(en)
|
2004-07-30 |
2006-02-09 |
Merck & Co., Inc. |
Indanone potentiators of metabotropic glutamate receptors
|
|
DE602005020313D1
(de)
|
2004-08-12 |
2010-05-12 |
Amgen Inc |
Bisaryl-sulfonamide
|
|
WO2006039212A2
(en)
|
2004-09-29 |
2006-04-13 |
Portola Pharmaceuticals, Inc. |
Substituted 2h-1,3-benzoxazin-4(3h)-ones
|
|
JP2008189549A
(ja)
|
2005-05-12 |
2008-08-21 |
Astellas Pharma Inc |
カルボン酸誘導体またはその塩
|
|
DE102005038947A1
(de)
|
2005-05-18 |
2006-11-30 |
Grünenthal GmbH |
Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
|
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
|
US7915410B2
(en)
|
2005-09-09 |
2011-03-29 |
Bristol-Myers Squibb Company |
Acyclic IKur inhibitors
|
|
ES2320042T3
(es)
|
2005-10-19 |
2009-05-18 |
F. Hoffmann-La Roche Ag |
Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
|
|
CA2630234A1
(en)
|
2005-11-23 |
2007-05-31 |
Ligand Pharmaceuticals Inc. |
Thrombopoietin activity modulating compounds and methods
|
|
AR058296A1
(es)
|
2005-12-09 |
2008-01-30 |
Kalypsys Inc |
Inhibidores de histona desacetilasa y composicion farmaceutica
|
|
MX2008013194A
(es)
*
|
2006-04-11 |
2008-12-01 |
Vertex Pharma |
Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
|
|
EP2086973B1
(en)
|
2006-10-11 |
2012-01-25 |
Amgen Inc., |
Imidazo- and triazolo-pyridine compounds and methods of use therof
|
|
AU2008211172A1
(en)
|
2007-01-30 |
2008-08-07 |
Biogen Idec Ma Inc. |
1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases
|
|
CA2677493A1
(en)
*
|
2007-02-05 |
2008-08-14 |
Xenon Pharmaceuticals Inc. |
Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
|
|
CL2008000835A1
(es)
|
2007-03-23 |
2008-10-03 |
Icagen Inc Pfizer Ltd |
Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
|
|
CA2687764A1
(en)
|
2007-05-25 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Ion channel modulators and methods of use
|
|
WO2008149965A1
(ja)
*
|
2007-06-07 |
2008-12-11 |
Astellas Pharma Inc. |
ピリドン化合物
|
|
US20090012103A1
(en)
|
2007-07-05 |
2009-01-08 |
Matthew Abelman |
Substituted heterocyclic compounds
|
|
WO2009010784A1
(en)
|
2007-07-13 |
2009-01-22 |
Astrazeneca Ab |
New compounds 955
|
|
JP5460589B2
(ja)
|
2007-07-13 |
2014-04-02 |
アイカジェン， インコーポレイテッド |
ナトリウムチャネル阻害物質
|
|
US20110092703A1
(en)
|
2007-08-10 |
2011-04-21 |
Nippon Chemiphar Co., Ltd. |
P2x4 receptor antagonist
|
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
|
AU2008345225A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
ES2518919T3
(es)
*
|
2008-05-14 |
2014-11-05 |
Astellas Pharma Inc. |
Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
|
|
CN102076660B
(zh)
|
2008-06-23 |
2014-01-08 |
安斯泰来制药有限公司 |
磺胺化合物或其盐
|
|
WO2010022055A2
(en)
|
2008-08-20 |
2010-02-25 |
Amgen Inc. |
Inhibitors of voltage-gated sodium channels
|
|
CA2747419C
(en)
|
2009-01-12 |
2014-07-08 |
Icagen, Inc. |
Sulfonamide derivatives
|
|
HUE034911T2
(hu)
|
2009-07-27 |
2018-03-28 |
Gilead Sciences Inc |
Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
|
|
WO2011016234A1
(en)
|
2009-08-04 |
2011-02-10 |
Raqualia Pharma Inc. |
Picolinamide derivatives as ttx-s blockers
|
|
JP5708936B2
(ja)
*
|
2009-09-25 |
2015-04-30 |
アステラス製薬株式会社 |
置換アミド化合物
|
|
WO2011059042A1
(ja)
|
2009-11-12 |
2011-05-19 |
武田薬品工業株式会社 |
芳香環化合物
|
|
WO2011063001A1
(en)
|
2009-11-18 |
2011-05-26 |
Concert Pharmaceuticals, Inc. |
Niacin prodrugs and deuterated versions thereof
|
|
TW201139406A
(en)
|
2010-01-14 |
2011-11-16 |
Glaxo Group Ltd |
Voltage-gated sodium channel blockers
|
|
SI2533638T1
(sl)
|
2010-02-12 |
2016-05-31 |
Nivalis Therapeutics, Inc. |
Novi inhibitorji S-nitrozoglutation reduktaze
|
|
WO2011153588A1
(en)
|
2010-06-10 |
2011-12-15 |
Biota Scientific Management Pty Ltd |
Viral polymerase inhibitors
|
|
WO2012005842A1
(en)
|
2010-06-30 |
2012-01-12 |
Cardiac Pacemakers, Inc. |
Lead having coil electrode with preferential bending region
|
|
WO2012004664A2
(en)
|
2010-07-07 |
2012-01-12 |
Purdue Pharma L.P. |
Analogs of sodium channel peptide toxin
|
|
JP5872552B2
(ja)
|
2010-07-09 |
2016-03-01 |
ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ |
化学化合物
|
|
WO2012004743A1
(en)
|
2010-07-09 |
2012-01-12 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
|
ES2526675T3
(es)
|
2010-07-09 |
2015-01-14 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
|
|
EP2593427B1
(en)
|
2010-07-12 |
2014-12-24 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
|
CA2804351A1
(en)
*
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
|
EP2593428B1
(en)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
|
EP2593431B1
(en)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
|
JP2013532184A
(ja)
*
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
|
|
JP2013531687A
(ja)
|
2010-07-16 |
2013-08-08 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ナトリウムチャネル遮断剤としてのピリジン化合物
|
|
DK2616465T3
(da)
|
2010-09-13 |
2016-02-01 |
Novartis Ag |
Triazin-oxadiazoler
|
|
WO2012039657A1
(en)
|
2010-09-22 |
2012-03-29 |
Astrazeneca Ab |
Novel chromane compound for the treatment of pain disorders
|
|
US9656959B2
(en)
|
2010-12-22 |
2017-05-23 |
Purdue Pharma L.P. |
Substituted pyridines as sodium channel blockers
|
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
|
KR101923367B1
(ko)
|
2011-02-02 |
2018-12-04 |
버텍스 파마슈티칼스 인코포레이티드 |
이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
|
|
AU2012296529A1
(en)
|
2011-08-17 |
2014-02-20 |
Amgen Inc. |
Heteroaryl sodium channel inhibitors
|
|
WO2013056232A2
(en)
|
2011-10-13 |
2013-04-18 |
Case Western Reserve University |
Rxr agonists compounds and methods
|
|
AU2012328561A1
(en)
|
2011-10-28 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
|
|
MX2014005304A
(es)
|
2011-10-31 |
2015-03-20 |
Xenon Pharmaceuticals Inc |
Biaril eter sulfonamidas y su uso como agentes terapeuticos.
|
|
ES2586213T3
(es)
|
2011-10-31 |
2016-10-13 |
Xenon Pharmaceuticals Inc. |
Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
|
|
WO2013072758A1
(en)
|
2011-11-15 |
2013-05-23 |
Purdue Pharma L.P. |
Pyrimidine diol amides as sodium channel blockers
|
|
WO2013086229A1
(en)
|
2011-12-07 |
2013-06-13 |
Amgen Inc. |
Bicyclic aryl and heteroaryl sodium channel inhibitors
|
|
ES2593533T3
(es)
*
|
2011-12-15 |
2016-12-09 |
Pfizer Limited |
Derivados de sulfonamida
|
|
CA2860553C
(en)
*
|
2012-01-04 |
2016-08-23 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
|
JP2015083542A
(ja)
|
2012-02-08 |
2015-04-30 |
大日本住友製薬株式会社 |
３位置換プロリン誘導体
|
|
US8889741B2
(en)
|
2012-02-09 |
2014-11-18 |
Daiichi Sankyo Company, Limited |
Cycloalkane derivatives
|
|
WO2013122897A1
(en)
|
2012-02-13 |
2013-08-22 |
Amgen Inc. |
Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
|
|
US9051311B2
(en)
|
2012-03-09 |
2015-06-09 |
Amgen Inc. |
Sulfamide sodium channel inhibitors
|
|
WO2013146969A1
(ja)
|
2012-03-29 |
2013-10-03 |
第一三共株式会社 |
新規二置換シクロヘキサン誘導体
|
|
CA2874621A1
(en)
|
2012-05-22 |
2013-11-28 |
Genentech, Inc. |
N-substituted benzamides and their use in the treatment of pain
|
|
US10071957B2
(en)
|
2012-07-06 |
2018-09-11 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
|
US9758480B2
(en)
|
2012-07-19 |
2017-09-12 |
Sumitomo Dainippon Pharma Co., Ltd. |
1-(cycloalkyl-carbonyl)proline derivative
|
|
AU2013334664A1
(en)
|
2012-10-26 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
|
|
JP2015535251A
(ja)
|
2012-10-26 |
2015-12-10 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
電位作動型ナトリウムチャネルにおいて選択的活性を有するベンゾオキサゾリノン化合物
|
|
EP2935257B1
(en)
|
2012-12-20 |
2018-02-07 |
Purdue Pharma LP |
Cyclic sulfonamides as sodium channel blockers
|
|
CN105026373B
(zh)
|
2013-01-31 |
2018-03-30 |
沃泰克斯药物股份有限公司 |
作为钠通道调节剂的吡啶酮酰胺
|
|
US20140296266A1
(en)
|
2013-03-01 |
2014-10-02 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
|
CN105263490B
(zh)
|
2013-03-14 |
2018-05-22 |
基因泰克公司 |
取代的三唑并吡啶及其使用方法
|
|
CA2898680A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech,Inc. |
Substituted benzoxazoles and methods of use thereof
|
|
US10179781B2
(en)
|
2013-03-15 |
2019-01-15 |
Chromocell Corporation |
Sodium channel modulators for the treatment of pain
|
|
WO2015051043A1
(en)
|
2013-10-01 |
2015-04-09 |
Amgen Inc. |
Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
|
|
JP6383418B2
(ja)
|
2013-11-27 |
2018-08-29 |
ジェネンテック， インコーポレイテッド |
置換ベンズアミド及びその使用方法
|